Loring Wolcott & Coolidge Fiduciary Advisors LLP MA Has $110,000 Stake in Boston Scientific Co. (NYSE:BSX)

Loring Wolcott & Coolidge Fiduciary Advisors LLP MA reduced its stake in Boston Scientific Co. (NYSE:BSX) by 8.8% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 1,233 shares of the medical equipment provider’s stock after selling 119 shares during the period. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA’s holdings in Boston Scientific were worth $110,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors also recently made changes to their positions in the stock. Newbridge Financial Services Group Inc. boosted its position in Boston Scientific by 12.8% in the fourth quarter. Newbridge Financial Services Group Inc. now owns 17,347 shares of the medical equipment provider’s stock valued at $1,549,000 after buying an additional 1,975 shares in the last quarter. Kestra Private Wealth Services LLC lifted its stake in shares of Boston Scientific by 21.1% in the 4th quarter. Kestra Private Wealth Services LLC now owns 33,153 shares of the medical equipment provider’s stock valued at $2,961,000 after acquiring an additional 5,767 shares during the last quarter. Stephens Inc. AR grew its position in Boston Scientific by 1.4% during the 4th quarter. Stephens Inc. AR now owns 10,546 shares of the medical equipment provider’s stock worth $942,000 after acquiring an additional 148 shares during the last quarter. Quotient Wealth Partners LLC increased its holdings in Boston Scientific by 6.0% in the 4th quarter. Quotient Wealth Partners LLC now owns 5,045 shares of the medical equipment provider’s stock worth $451,000 after purchasing an additional 285 shares in the last quarter. Finally, Entropy Technologies LP bought a new position in Boston Scientific in the fourth quarter valued at about $214,000. 89.07% of the stock is owned by institutional investors.

Boston Scientific Stock Up 0.3 %

BSX stock opened at $105.33 on Monday. The stock has a fifty day moving average of $94.88 and a 200-day moving average of $87.21. Boston Scientific Co. has a fifty-two week low of $64.39 and a fifty-two week high of $107.17. The company has a market capitalization of $155.24 billion, a price-to-earnings ratio of 84.26, a PEG ratio of 2.79 and a beta of 0.80. The company has a debt-to-equity ratio of 0.44, a quick ratio of 1.02 and a current ratio of 1.48.

Boston Scientific (NYSE:BSX) last posted its quarterly earnings results on Wednesday, February 5th. The medical equipment provider reported $0.70 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.65 by $0.05. Boston Scientific had a net margin of 11.07% and a return on equity of 18.11%. As a group, equities research analysts predict that Boston Scientific Co. will post 2.83 earnings per share for the current year.

Insider Activity at Boston Scientific

In related news, EVP Arthur C. Butcher sold 17,313 shares of the business’s stock in a transaction that occurred on Monday, February 3rd. The shares were sold at an average price of $101.80, for a total transaction of $1,762,463.40. Following the completion of the transaction, the executive vice president now owns 5,502 shares of the company’s stock, valued at approximately $560,103.60. The trade was a 75.88 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Wendy Carruthers sold 6,983 shares of the business’s stock in a transaction on Monday, December 2nd. The shares were sold at an average price of $90.78, for a total transaction of $633,916.74. Following the transaction, the executive vice president now owns 29,308 shares of the company’s stock, valued at $2,660,580.24. This trade represents a 19.24 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 47,302 shares of company stock worth $4,464,725. 0.50% of the stock is owned by company insiders.

Analysts Set New Price Targets

Several analysts have recently weighed in on the company. Needham & Company LLC restated a “hold” rating on shares of Boston Scientific in a report on Thursday. Sanford C. Bernstein boosted their target price on shares of Boston Scientific from $92.00 to $100.00 and gave the stock an “outperform” rating in a report on Thursday, October 24th. Raymond James raised their price target on shares of Boston Scientific from $119.00 to $122.00 and gave the company a “strong-buy” rating in a research note on Thursday. Piper Sandler boosted their price objective on shares of Boston Scientific from $95.00 to $115.00 and gave the stock an “overweight” rating in a research note on Monday, February 3rd. Finally, Canaccord Genuity Group raised their target price on Boston Scientific from $98.00 to $101.00 and gave the stock a “buy” rating in a research report on Monday, December 9th. One investment analyst has rated the stock with a hold rating, twenty-two have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Buy” and a consensus target price of $106.00.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.